you look at gilead, amgen and celgene.ilead trading 7 times earnings down from 40 times beginning of 2014. it came down because that's around the time the drug pricing pressure started to ratchet up. we talked about drug pricing when there were real companies like gilead. it started to come down. gilead is trading at this level because people don't know what is going to happen after they cure everybody of hepatitis-c. folks are asking who are they going to buy. they think it should be trading higher. >> how does amgen compare? >> a higher multiple trading 20 times earnings compared with gilead's seven times. sorry. trading 15 times down from a high of 20 times. all these biotechs are down right now. celgene is the same. people say these are really great looking stocks. they've got a lot of earnings visibility. if you look at the top six pi techs in the ibb, they are trading 18 times 2016 earnings compared to 14, 15 for the s&p 500. they've got earnings expectations for 11% this year. that's why analysts are arguing these b

i like amgen. i think amgen is very good. and then let's put gilead in that mix. those are high cross stocks. they do better. i'm not as concerned or negative as most of the people although all right. sometimes the market wants to go lower. we have to accept that. when it gets this negative i am urging actually calm. i want you to consider even as the market goes lower picking a favorite stock that's now at your price. all right on "mad money" tonight i already examined the winners and losers in 2015. tonight i'm eyeing the nasdaq. could the crash in crude contue? mr. wonderful himself. kevin o'leary can brighten up a little bit of sunshine in the show. stick with cramer. >> you're out of your mind putting a $10 million value on this. >> don't miss a second of "mad money." follow @jimcramer on twitter. have a question, tweet cramer. #"mad tweets." send jim an e-mail to head to madmoney.cnbc.com. >> i am urging you to remember that stocks can go up too. it's in this difficult environment that you need to be all week we have been examining the biggest winners of 201

i've got 10% of my equity investments in amgen. i don't invision needing the money or at least ten years. that's perfect. you are in great shape. it's a very inexpensive stock. you get a company with great growth at 9 times earnings. that's because everybody hates everything. with being real money it was talking about disgust that turns a bear market around. i have to tell you, it's not fear it's disgust. i'm getting a little disgusted. want to dip your toe in go for yield protection. capital until it's over. how much lower do we have to go until this market can find a bottom. i'm going off the chart to find out you may not like what you see. when companies dominate the competition you can be the winner. i'm checking out stocks that weeded out the weak in their industry to see if they can pay. and the man, the myth, the shark. tonight he is lending his entrepreneurial eye to help spot the market's next hot trend. you don't want to miss it. stick with cramer. >> don't miss a second of "mad money." follow @jimcramer on twitter. have

amgen is inexpensive. inexpensive stock. i'm intrigued.ed with celgene but disheartened to see bob step up to executive chairman. you want him at the helm. he has a deep bench. i'm sure he's right, which is why i think celgene is a buy. if t the jpmorgan is usually a time you want to buy stocks. >> the guidance from anthem and aetna not bad. >> no. balance that against mckesson which is horrendous. rite-aid, maybe losing that contract. >> the three big gainers on the dow, intel, coke and apple are all upgrade related. you already covered the intel call. stifel takes coke to a buy. >> i think coke is doing well. i do. people just say, well, they're yawning, coke is hedged against the yen and hedged against the euro, not against some other currencies. there's been a lot of changes put through, and you will start seeing better numbers from coca-cola after a long period where the stock has been stagnant. i think it's a buy. i also like pepsico here. also doing a great job. >> the stock has been a decent stock. i continue to wonder -- again, th

. >>> the supreme court threw out a ruling in favor of amgen employees who said they lost money in the company stock ownership program. the original lawsuit from 2007 said the value of the plaintiffs retirement plans fell when the stock dropped. it was revealed the company concealed negative clinic study results and marketed it for off label uses that were unsafe. the court said the original rules was incorrect and sent the case back to lower courts. shares fell more than 1.5%. >>> as we mentioned just a bit earlier about a quarter of the s&p 500 scheduled to report earnings. it's a big week. we look at why wall street will be focused on a trio of the big names. >> reporter: it has been a tough start to the year for tech. sector is down some 7%. 33 tech stocks were nearly 50% in the s&p 500 are in bare market territory. meaning a drop of 20% from a recent high. investors are concerned about global economic growth and that's a problem for tech given that 60% of the sectors revenue comes from overseas. despite the sector's drop, investment strategist remain on the sidelines for now. >> t

amgen slightly in the red.e mentioned oil and may have rallied on possible opec production cuts but my next guest says he's not sure we've seen the bottom. tom, good to have you with us. you think it could get worse here? >> i think it could definitely get worse for crude. when we really look at it, nothing happened today. you have russia saying that they want to have a dialogue with opec countries, which one would expect them to say. and all of the rally and volume was in the front month. i think these were speeshs reasons and i think the next 90 days be going to be incredibly ugly for oil fundamentals. >> why? >> there's a glut. you could put numbers on this and say there's 2 million or $3 million barrels a day. refineries are just starting to get into the middle innings of their maintenance season and that means less demand. this is the tough spot. then you get better in the spring and summer and then the next tough spot comes in the fall when refineries don't need as much crude oil. >> are we not yet in a p

. >>> strong sales of its blockbuster arthritis drug enbrel helped amgen beat earnings and saw them rise 40%. the world's biggest biotech drugmaker raised its outlook for 2016. shares initially rose in extended hours after falling more than 1% today to 148.35. >>> the wounded warrior project that supports veterans has come under fire for its lavish spending. according to the charity rating agency charity navigator only 60% of wounded warrior project's money goes towards helping veterans compared to similar charities who spend significantly more. how do you know if your charitable contributions are really going where they are intended to? michael thatcher joins us president and ceo of charity navigator, joins us now. nice to have you here welcome. >> thank you very much, a pleasure to be here. >> wounded warrior pushed back on the various news reports about their spending saying in order to raise significant amounts of cash you have to spend. is that a valid argument? or not? >> i think it's a valid argument if you can also show the effectiveness of your spending. so am i -- as i'm invest

am 73ears old and i m most equity invest pofolio mual nds i retained shaof amgen ve g 10%my e investments en. i dot si mo at asten ar 's pct. it's ainexpensstock. u get a mpwith great growth ames earnings. thatecau evebo hes everything th being rmoney itas tag abt ust turns a mt around. i ha t haveo teou, 's not fear it'disg nt tdip ur t in or yiprotecti it c'tp u eserve pitauntil it's over. w much lowero have to g untithis market can nd a om. gointhe art to fd out y nolike what u sewhenompani datthe competition you n he winner. i'checking out stocks that eded outhe weak in tir industry to e they can y. and the man, the myt the shark. tonight hes g his trepneurial eye toelp ot the rk'st hot en yodon'want to miss it. stick wi cramer. >>iss a f "mad money." fo @mcmeonwier haveuest tet crer, adts. se jn ma to madmoney@cnbc.co give ca madmoney@cc.com. >>> te >>after la wk's ci sell off how muclor do we have tgo bwe can feel mftablor at ast chnici com etas finally . a very icult d ry imrtant estihichwh wegoing f the ts. she is the phenomenatechnician that runhe website. one of my coeaes at th

one ceo issued disappointing guidance, and amgen was pulled it down with biotech, and vertex after the close on friday, its ceo also commenting in a conference that the drug pricing in the future will depend on the outcome of the coming election, and apple saying it had reached 10 million users for its music service, and it got a couple of upgrades, amazon rebounding, and intel, as well, rounding out the top tech reporters. julie hyman, bloomberg, new york. emily: all right, thank you, julie. in time, all bets are on for fantasy sports, at least for now. a judge ruled drafting's will be able to keep going, along with sand dual -- a judge ruled that draft king and fan duel can keep going. at least for now. and coming up, coming out swinging in retaliation. thus, surprises between netflix and amazon at the golden globes. it details, later. ♪ emily: it took spotify six years to hit one level, putting to the financial times, reporting the apple membership site after they launched a service compatible with and speaking of stats, ramping up with some major new numbers. it registered more tha

>> well, radius is a speculative stock and you have very solid companies like amgen and celgene getting crushed. you have to expect this one will get crushed more and up more. you have to understand it was pure speculation. everybody is allowed to speculate. you should speculate in one or two positions out of ten but it is a speculative stock and this is what happens. >> brad in new york, brad. >> booyah, cramer. i just want to say thanks for having my pack. >> doing my best, man. what's going on. >> my question was about cig group. at 6 times earnings is this a buy? >> well, it's a financial and the financials are starting to go down because people feeling like interest rates aren't going higher. they're caught in a rock and a though it is at the 52 week low. i don't see a lot of reasons why i need to be in it. let's go to corey in massachusetts. >> jim, thank you for having me. i'm in a bio tech with great results and the $800 million market that's flowing 150%. what's your take on sgyp? >> i know that there was -- i saw a downgrade by city the other day. i have to check my bio tech b

you are well ahead of a bunch of companies, amgen, lily, teva.llergan came on and talked about its migraine formulation that it's bullish about. they'll be teaming up with pfizer. how do you compete against giant companies that say they have a better mousetrap here? >> first and foremost, again, i think the alder scientists have discovered a therapeutic that we believe has best in class properties. and to be honest, in a word, we think alder can lead the way in terms of innovation, how we're viewing the best way to introduce this therapeutic to patients. and we can bring novelty to the table that we believe some of the bigger place are not able to do. >> you were able to raise some capital. when you go down like this, there's a lot of biotech companies that are so small now because the market is taking us down, we're going to get a call from a major pharmaceutical company and take out our upside by offering an attractive premium to people who just got in but it's disappointing if you take a long term view. >> i would agree with that. obviously th

pretty warm in january, almost february >>> the amgen tour of california announced the race. it will run to the north. it will start in san diego, covers 800 miles and ends up in sacramento. the only bay area stage will actually be in santa rosa. the men's race begins may 15th and the women's race begins may 19th and includes again a stage in santa rosa for the women as well. >> time is 6:18. he is really, really back now. hearing more from the washington post reporter who spent 18 months in and iranian prison. in 22 minutes, why he says his interrogators told him he would not be free. >>> first, the zika virus continues to spread here in the u.s. the steps that federal regulators are taking to protect our blood supply. ♪. >> all right. cheesy song >> yeah, that's cheesy. >> what one man's cheesy song is another man's steak, right. >> be fair. >> this is from the jacksons. the theme is cheesy song. dan baker requested it. bust a move >> go ahead and bust a move if there is a special song you want to hear, let us know. we'll play your request here. >> you know all the words, s

we did have some misses and the big one came from amgen. also electronic arts missed as well.pple. i love the action on apple-related names after the bell. all up big, 4%, 2%, 3%. i know you are probably afraid to buy these picks. if you have something you have like, this is a good time to start nibbling. keep 10 to 15% in cash, there will be more opportunities down the line. a man and his girlfriend were arrested at disneyland paris. they were arrested with guns and a copy of the quran. and then you totaled him. you two had been through everything together. two boyfriends, three jobs... you're like nothing can replace brad. then liberty mutual calls, and you break into your happy dance. if you sign up for better car replacement™, we'll pay for a car that's a model year newer with 15,000 fewer miles than your old one. see car insurance in a whole new light. liberty mutual insurance. charles: french police arrested a 20-year-old man and his girlfriend at a disneyland theme park hotel ap after he was found with the quran, ammo and two guns in his suitcase. joining me now. gillia